Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Nishimura JI, Ando K, Masuko M, Noji H, et al. Haematologica 2022;107:1483-1488.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nishimura JI, Ando K, Masuko M, Noji H, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2022;107:1483-1488.
PMID: 35263983